Cargando…

POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes

Detalles Bibliográficos
Autores principales:	Tritschler, Tobias, Le Gal, Grégoire, Brosnahan, Shari, Carrier, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians. Published by Elsevier Inc. 2022
Materias:	Editorial: Point and Counterpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923527/ https://www.ncbi.nlm.nih.gov/pubmed/35469670 http://dx.doi.org/10.1016/j.chest.2022.01.036

Ejemplares similares

Rebuttal From Dr Tritschler et al
por: Tritschler, Tobias, et al.
Publicado: (2022)

COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
por: Jimenez, David, et al.
Publicado: (2022)

POINT: Tracheostomy in Patients With COVID-19: Should We Do It Before 14 Days? Yes
por: Brenner, Michael J., et al.
Publicado: (2021)

POINT: Should Fellowship Interviews Remain Exclusively Virtual? Yes
por: Çoruh, Başak
Publicado: (2021)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Should Requirements for Nurses Be Relaxed During Health Emergencies?
por: Gardenier, Donald, et al.
Publicado: (2021)

Should Statutory Restrictions on NP Practice Be Relaxed During Emergencies?
por: Gardenier, Donald, et al.
Publicado: (2021)

Are the days of closed pleural biopsy over? Yes
por: Patel, Dharmesh
Publicado: (2015)

COUNTERPOINT: Tracheostomy in Patients With COVID-19: Should We Do It Before 14 Days? No
por: Pandian, Vinciya, et al.
Publicado: (2021)

In Vivo Studies Should Take Priority When Defining Mechanisms of Intestinal Crypt Morphogenesis
por: Guiu, Jordi, et al.
Publicado: (2021)

Rebuttal to: In Vivo Studies Should Take Priority When Defining Mechanisms of Intestinal Crypt Morphogenesis
por: Sugimoto, Shinya, et al.
Publicado: (2021)

POINT: Is Considering Social Determinants of Health Ethically Permissible for Fair Allocation of Critical Care Resources During the COVID-19 Pandemic? Yes
por: White, Douglas B., et al.
Publicado: (2022)

Should Local Excision After Neoadjuvant Therapy Be Included in the National Guidelines for the Treatment of Locally Advanced Rectal Cancer?
por: Aref, Amr, et al.
Publicado: (2022)

Advanced Imaging Tools Rather Than Hemodynamics Should Be the Primary Approach for Diagnosing, Following, and Managing Pulmonary Arterial Hypertension
por: Gerges, Mario, et al.
Publicado: (2015)

Point: Steady Progress and Current Challenges in Clinical Islet Transplantation
por: Mineo, Davide, et al.
Publicado: (2009)

Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target
por: Ceriello, Antonio
Publicado: (2010)

Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?
por: Lachin, John M.
Publicado: (2010)

Point: Incident Exposures, Prevalent Exposures, and Causal Inference: Does Limiting Studies to Persons Who Are Followed From First Exposure Onward Damage Epidemiology?
por: Vandenbroucke, Jan, et al.
Publicado: (2015)

COUNTERPOINT: Should Fellowship Interviews Remain Exclusively Virtual? No
por: Allam, J. Shirine
Publicado: (2021)

Counterpoint: Clinical Islet Transplantation: Not Ready for Prime Time
por: Khan, Mahfuzul H., et al.
Publicado: (2009)

A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: A1C remains the gold standard outcome predictor in diabetic dialysis patients
por: Kalantar-Zadeh, Kamyar
Publicado: (2012)

A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: Time to dispense with the hemoglobin A1C in end-stage kidney disease
por: Freedman, Barry I.
Publicado: (2012)

Response to commentary “Zinc is decreased in prostate cancer: an established relationship of prostate cancer!”
por: Banas, Agnieszka Maria, et al.
Publicado: (2010)

Counterpoint: Postprandial Glucose Levels Are Not a Clinically Important Treatment Target
por: Davidson, Mayer B.
Publicado: (2010)

Counterpoint: Intensive Glucose Control and Mortality in ACCORD—Still Looking for Clues
por: Riddle, Matthew C.
Publicado: (2010)

Mitochondrial Deficiency Is Associated With Insulin Resistance
por: Goodpaster, Bret H.
Publicado: (2013)

“Deficiency” of Mitochondria in Muscle Does Not Cause Insulin Resistance
por: Holloszy, John O.
Publicado: (2013)

Glucose Variability: Where It Is Important and How to Measure It
por: DeVries, J. Hans
Publicado: (2013)

Glucose Variability
por: Service, F. John
Publicado: (2013)

Insulin Analogs—Is There a Compelling Case to Use Them? No!
por: Davidson, Mayer B.
Publicado: (2014)

2012 ESC STEMI guidelines and reperfusion therapy: Evidence base ignored, threatening optimal patient management
por: Terkelsen, Christian Juhl, et al.
Publicado: (2013)

Validity of Meta-analysis in Diabetes: Meta-analysis Is an Indispensable Tool in Evidence Synthesis
por: Golden, Sherita Hill, et al.
Publicado: (2013)

Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations
por: Home, Philip D.
Publicado: (2013)

Self-Monitoring of Blood Glucose in Noninsulin-Using Type 2 Diabetic Patients: It is time to face the evidence
por: Malanda, Uriëll L., et al.
Publicado: (2013)

Self-Monitoring of Blood Glucose in Noninsulin-Using Type 2 Diabetic Patients: Right answer, but wrong question: self-monitoring of blood glucose can be clinically valuable for noninsulin users
por: Polonsky, William H., et al.
Publicado: (2013)

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
por: Nauck, Michael A.
Publicado: (2013)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment
por: Umpierrez, Guillermo E., et al.
Publicado: (2013)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

A Critical Analysis of the Clinical Use of Incretin-Based Therapies : Are the GLP-1 therapies safe?
por: Butler, Peter C., et al.
Publicado: (2013)

Vandenbroucke and Pearce Respond to “Incident and Prevalent Exposures and Causal Inference”
por: Vandenbroucke, Jan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p3t9pc8t2cs5vta3o6rd2gslk7